
    
      To show that the use of intravenous levetiracetam(LEV;Keppra)for seizure prophylaxis in the
      Neuroscience Intensive Care Unit will result in fewer adverse effects compared to the current
      standard of care anticonvulsant(phenytoin) and will be at least as effective as phenytoin in
      preventing clinical and sub-clinical seizure activity.
    
  